Design and synthesis of adamantyl-substituted flavonoid derivatives as anti-inflammatory Nur77 modulators: Compound B7 targets Nur77 and improves LPS-induced inflammation in vitro and in vivo

Bioorg Chem. 2022 Mar:120:105645. doi: 10.1016/j.bioorg.2022.105645. Epub 2022 Jan 29.

Abstract

In continuing our study on discovering new Nur77-targeting anti-inflammatory agents with natural skeletons, we combined adamantyl group and hydroxamic acid moiety with flavonoid nucleus, synthesized three series of flavonoid derivatives with a similar structure like CD437, and evaluated their activities against LPS-induced inflammation. Compound B7 was found to be an excellent Nur77 binder (Kd = 3.55 × 10-7 M) and a potent inhibitor of inflammation, which significantly decreased the production of cytokines in vitro, such as NO, IL-6, IL-1β, and TNF-α, at concentrations of 1.25, 2.5, and 5 μM. Mechanistically, B7 modulated the colocalization of Nur77 at mitochondria and inhibited the lipopolysaccharides (LPS)-induced inflammation via the blockade of NF-κB activation in a Nur77-dependent manner. Additionally, B7 showed in vivo anti-inflammatory activity in the LPS-induced mice model of acute lung injury (ALI). These data suggest that the Nur77-targeting flavonoid derivatives can be particularly useful for further pharmaceutical development for the treatment of inflammatory diseases such as ALI.

Keywords: Acute lung injury; Anti-inflammation; Flavonoid derivatives; Nur77.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Lung Injury* / chemically induced
  • Acute Lung Injury* / drug therapy
  • Animals
  • Anti-Inflammatory Agents / adverse effects
  • Cytokines
  • Flavonoids / pharmacology
  • Flavonoids / therapeutic use
  • Inflammation / chemically induced
  • Inflammation / drug therapy
  • Lipopolysaccharides* / adverse effects
  • Mice
  • NF-kappa B

Substances

  • Anti-Inflammatory Agents
  • Cytokines
  • Flavonoids
  • Lipopolysaccharides
  • NF-kappa B